Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer : Episode 1
Opinion
Video
Biomarker Testing Best Practices in HR+/HER2- mBC
Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PI3 alterations, AKT alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.
- Please discuss the role of biomarker testing in HR+/HER2- breast cancer.
- What are the most clinically relevant genomic tests or biomarker assays used in HR+/HER2- breast cancer?
- How do the results of these tests influence prognosis and treatment decision-making?
Related Videos
Related Content
